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Abstract
Background: Several new drugs are approved for treatment of patients with multiple myeloma (MM), but no
validated biomarkers are available for the prediction of a clinical outcome. We aimed to establish whether
pretreatment blood and bone marrow plasma concentrations of major cytokines and angiogenic factors (CAFs) of
patients from a phase 3 trial of a MM treatment could have a prognostic and predictive value in terms of response
to therapy and progression-free and overall survival and whether these patients could be stratified for their
prognosis.
Methods: Blood and bone marrow plasma levels of Ang-2, FGF-2, HGF, VEGF, PDGF-β, IL-8, TNF-α, TIMP-1, and
TIMP-2 were determined at diagnosis in MM patients enrolled in the GIMEMA MM0305 randomized controlled trial
by an enzyme-linked immunosorbent assay (ELISA). These levels were correlated both reciprocally and with the
type of therapy and patients’ characteristics and with a group of non-MM patients as controls.
Results: No significant differences were detected between the blood and bone marrow plasma levels of
angiogenic cytokines. A cutoff for each CAF was established. The therapeutic response of patients with blood
plasma levels of CAFs lower than the cutoff was better than the response of those with higher levels in terms of
percentage of responding patients and quality of response.
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Conclusion: FGF-2, HGF, VEGF, and PDGF-β plasma levels at diagnosis have predictive significance for response to
treatment. The stratification of patients based on the levels of CAFs at diagnosis and their variations after therapy is
useful to characterize different risk groups concerning outcome and response to therapy.
Trial registration: Clinical trial information can be found at the following link: NCT01063179
Keywords: Angiogenic factors, Multiple myeloma, Overall survival, Progression-free survival, Response rate,
Background
Multiple myeloma (MM) is the second most common
hematologic cancer after non-Hodgkin’s lymphoma, with
a higher incidence in the elderly. Patients older than
70 years account for 56% of new cases and for 73% of all
deaths from MM [1]. Combined melphalan-prednisone
has been the standard of care for more than 40 years
and has been found to be associated with a median sur-
vival of 29 to 37 months [2–4]. Today, the availability of
novel agents, such as the first-in-class proteasome in-
hibitor bortezomib and the immunomodulatory drugs
thalidomide and lenalidomide, has significantly im-
proved the clinical outcome of these patients [5–13].
Accurate identification of high-risk patients and risk
stratification are crucial in improving outcomes for MM
patients, but considerable heterogeneity exists in their
overall survival. Although a large number of prognostic
markers have been described, including disease burden
(Durie-Salmon staging system, International Staging Sys-
tem, magnetic resonance imaging, (18F)fluorodeoxyglu-
cose positron emission tomography, presence of
extramedullary disease or plasma-cell leukemia), host
factors (age, performance status, and renal function),
tumor biology (proliferation rate, conventional cytogen-
etics, interphase fluorescence in situ hybridization, and
gene expression profiling), and depth of response to
therapy [14–18], none of them completely explains the
heterogeneity seen in this tumor.
To further complicate matters, some of the new treat-
ments appear to overcome the high risk defined by one
or more of these prognostic factors [19, 20]. With the
increased treatment options, the ability of some treat-
ments to overcome certain risk factors, and the availabil-
ity of markers to define risk categories, risk stratification
in the management of MM is becoming an important
issue [21]. The achievement of a uniform risk stratifica-
tion system would also allow a better comparison of pa-
tient groups across different trials [22].
Angiogenesis is a constant hallmark of MM progres-
sion and has prognostic potential. The pathophysiology
of MM-induced angiogenesis involves both direct pro-
duction of angiogenic cytokines by plasma cells and their
induction within the bone marrow microenvironment
[23]. Moreover, inhibitors of the vascular endothelial
growth factor (VEGF) pathway, including bevacizumab
and tyrosine kinase inhibitors such as sorafenib, suniti-
nib, and pazopanib, have been shown to prolong
progression-free survival (PFS) and overall survival (OS)
[24–28] and are in fact approved for the treatment of
solid cancer.
It has been previously demonstrated that the plasma
levels of cytokines and angiogenic factors (CAFs) de-
crease after therapy in patients with cancer, and this may
be relevant for treatment response and PFS [29–32].
Here, we demonstrate that high levels of CAFs are nega-
tive prognostic factors in patients with MM and seem to
be predictive of relative benefit from therapy. Moreover,
the stratification of patients based on CAF levels at diag-
nosis is useful to detect different risk groups for out-
come and response to therapy.
Methods
Patients
Patient characteristics are reported in Table 1. This
study has been carried out on MM patients enrolled in
the multicenter clinical trial GIMEMA-MM0305, with
the participation of 61 centers in Italy from May 2006 to
January 2009. The study compared the combination
bortezomib-melphalan-prednisone-thalidomide followed
by maintenance with bortezomib-thalidomide
(VMPT-VT) with bortezomib-melphalan-prednisone
(VMP) administered for nine cycles without mainten-
ance. The details and results of the trial have been pub-
lished previously [33–35]. Clinical protocol and
informed consent documents were approved by the par-
ticipating local institution’s review boards, and the trial
was undertaken in accordance with the International
Conference on Harmonization Guidelines for Good
Clinical Practice and the amended Declaration of
Helsinki. Patients without MM or other tumors (patients
with stage I arterial hypertension without organ damage
and without other diseases) who gave their consent were
used as controls.
Methods
Before starting the treatment, peripheral blood and bone
marrow plasma (the initial 1 ml of bone marrow aspir-
ate) samples were collected into EDTA-containing tubes.
Both blood and bone marrow plasma samples from 124
of 511 patients enrolled in the study (24%) were available
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for analysis. Plasma was separated by centrifugation
(2,000 rpm for 20 min at 4 °C) within 1 h from blood
drawing and aliquoted into multiple cryovials. Plasma
samples were stored at − 80 °C until use. Before analysis,
plasma samples were thawed slowly in an ice bath and
all analyses were done from a one-off thaw sample.
CAFs were measured by using Q-Plex™ Array Human
Angiogenesis Antigen (Quansys Biosciences, Logan,
Utah) allowing the simultaneous quantification of the
following factors: angiopoietin-2 (ANG-2), fibroblast
growth factor-2 (FGF-2), hepatocyte growth factor
(HGF), interleukin-8 (IL-8), platelet-derived growth
factor-BB (PDGF-BB), tissue inhibitor of matrix
metalloproteinase-1 and 2 (TIMP-1, TIMP-2), tumor ne-
crosis factor-alpha (TNF-α), and vascular endothelial
growth factor (VEGF), according to the manufacturer’s
instructions. Secreted levels of CAFs were quantified
through Q-View Software (Quansys Biosciences, Logan,
Utah) in triplicate samples, and the mean results were
used in biomarker analysis.
Statistical analysis
In the first step, CAF levels were measured in the blood
and bone marrow plasma samples of MM patients to as-
sess whether significant differences could be detected in
the two compartments by Student’s t test (p values less
than 0.05 was considered significant). Since no signifi-
cant differences between the two compartments were
detected (see the “Results” section), subsequent analyses
were carried out using plasma samples from the periph-
eral blood. With the Student t test, the CAF levels in the
plasma samples of the MM patients were compared with
those of controls.
In the second phase, plasma levels of CAFs were mea-
sured as an independent variable to predict binary re-
sponse status (≥VGPR vs < VGPR) by logistic regression
analysis. CAF plasma levels were also correlated as a
continuous variable with tumor response by linear re-
gression and logarithmic transformation to normalize
CAF values. The correlation between log-CAFs and
tumor response was approximately linear. Selection of
individual CAF markers from the screening phase was
done on the basis of results of median cutoff, ROC curve
estimation of cutoff, and logistic regression analysis be-
tween dichotomized tumor response and CAF plasma
levels. We assessed the association between CAF plasma
levels and progression-free survival (PFS) with the Cox
proportional hazard model.
To establish whether plasma levels of any CAF might
have prognostic or predictive significance, the
Kaplan-Meier method was used to analyze PFS and OS.
We used the Cox regression model to verify significant
differences noted in Kaplan-Meier curves for both treat-
ment groups between a high- and a low-CAF subgroup,
defined by the respective median CAF plasma levels.
Sensitivity analyses confirmed that median cutoff
achieved the most significant segregation of clinical
benefit. To assess the potential differential effects of
baseline CAF concentrations between two treatment
groups, a treatment versus CAF status interaction term
was included in the Cox model analysis for PFS, with
treatment group and CAF status as two additional inde-
pendent variables. CAF plasma levels with a significant
interaction value with treatment were regarded as pre-
dictive. A post hoc analysis was done to adjust for mul-
tiple testing of CAF markers with the Bonferroni test.
Table 1 Patients’ characteristics
Patients Controls
Total VMP VMPT
n 124 53 71 54
Age 71 (56–85) 71 (60–85) 71 (56–85) 69 (54–88)
Sex (M/F) 58/66 24/29 34/37 24/30
Type of MM NA
IgG (%) 71 (57.2) 31 (58.5) 46 (64.8)
IgA (%) 28 (22.6) 12 (22.6) 14 (19.8)
BJ (%) 25 (20.2) 10 (18.9) 11 (15.4)
Stage (D&S) NA
IIA (%) 14 (11.3) 5 (9.4) 9 (12.7)
IIIA (%) 102 (82.3) 45 (84.9) 57 (80.3)
IIIB (%) 8 (6.4) 3 (5.7) 5 (7)
ISS stage NA
1
26
8 18
2
42
21 21
3
21
6 15
Missing data
35
18 17
Cytogenetics NA
High risk
28
11 17
Standard risk
36
16 20
Missing data
60
26 34
Response
CR (%) 47 (37.9) 14 (26.4) 33 (46.6)
VGPR (%) 27 (21.8) 11 (20.8) 16 (22.6) NA
PR (%) 38 (30.6) 19 (35.8) 19 (26.8)
SD (%) 12 (9.7) 9 (17) 3 (4.2)
Relapse (Y/N) 80/44 39/14 41/30 NA
Death (Y/N) 54/70 22/31 32/39 NA
NA not applicable
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Exploratory analyses included correlation between CAF
plasma levels and Eastern Cooperative Oncology Group
(ECOG) performance status, Durie & Salmon stage,
International Staging System stage, Cytogenetic risk, and
age and sex hierarchical clustering (unweighted pair
group method with arithmetic mean, unweighted aver-
age, and Euclidean distance for similarity measure) to as-
sess a multiple-CAF signature association with PFS or
OS (Kaplan-Meier method for PFS and OS, and Cox re-
gression models to assess differences). All statistical ana-
lyses were done with SPSS software.
Results
Biological samples (blood and bone marrow) from 124
MM patients randomly assigned to receive VMPT-VT
(53 pts) or VMP (71 pts) in the GIMEMA MM0305
phase III clinical trial and blood plasma samples from 54
control subjects were available for this study. Baseline
demographic and disease characteristics are reported in
Table 1.
We evaluated the concentration of ANG-2, FGF-2,
HGF, IL-8, PDGF-BB, TIMP-1, TIMP-2, TNF-α, and
VEGF that are the major cytokines involved in angiogen-
esis in MM and other cancers [36] and, as previously
demonstrated [37] in MM patients, directly correlate
with disease activity and increase with progression.
Moreover, plasma levels of CAFs are directly related to
disease response to therapy in hematologic and solid tu-
mors [29–32].
Our results showed that there were no differences in
the levels of the studied CAFs between the peripheral
blood and bone marrow plasma samples of MM patients
(Fig. 1, Additional file 1: Table S1), indicating that the
concentrations of circulating cytokines well reflect those
of the bone marrow and could be used for all subse-
quent analyses. As expected, the plasma levels of CAFs
in MM patients were significantly higher compared to
controls (p < 0.0001 for all CAFs). In addition, the levels
of CAFs were found to be significantly related to MM
response to therapy (Fig. 2) with the exception of
Fig. 1 Analysis of the CAF levels in blood and bone marrow plasma samples of MM patients. No differences are evident in their concentration
between peripheral blood and bone marrow samples. Significantly higher levels of CAFs are detected in blood and bone marrow samples of MM
patients as compared with control subjects (p < 0.0001 for all cytokines)
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TIMP-1 and TIMP-2. More precisely, low levels of
ANG-2 (p < 0.05), FGF-2 (p < 0.005), HGF (p < 0.05),
IL-8 (p < 0.05), PDGF-BB (p < 0.005), TNF-α (p < 0.05),
and VEGF (p < 0.005) were indicative of more profound
response (very good partial response [VGPR] or better
in all patients, with no evident differences between the
two therapeutic regimens (VMPT-VT vs VMP: p = 0.1).
On the basis of ROC curve estimation of cutoff and lo-
gistic regression analysis between dichotomized tumor
response and CAF plasma levels, a cutoff for each cyto-
kine was established that could be used to discriminate
the probability of response to therapy of MM patients
with high sensitivity and specificity (Additional file 1:
Table S2). Seventy-four patients had the best degree of
tumor response (≥VGPR) and were termed good re-
sponders, whereas 50 had the smallest degree of tumor
response (< VGPR) and were termed poor responders.
Among the seven CAFs that were shown to be signifi-
cantly related to MM response to therapy (Fig. 2), low
(relative to median) concentrations of ANG-2 (p <
0.0001), FGF-2 (p < 0.0001), HGF (p < 0.0001), IL-8 (p <
0.0001), PDGF-BB (p < 0.0001), TNF-α (p < 0.001), and
Fig. 2 Response rate of MM patients based on CAF levels. The blood levels of CAFs significantly correlate with MM response to therapy. Lower
levels of ANG-2 (p < 0.05), FGF-2 (p < 0.005), HGF (p < 0.05), IL-8 (p < 0.05), PDGF-BB (p < 0.005), TNF-α (p < 0.05), and VEGF (p < 0.005) are indicative
of more profound response, VGPR or better, in all patients, with no evident differences between the two therapy regimens (VMPT-VT vs
VMP: p = 0.1)
Saltarella et al. Journal of Hematology & Oncology            (2019) 12:4 Page 5 of 10
VEGF (p < 0.0001) highly correlated with best response
(Additional file 1: Table S2).
In terms of survival, PFS correlated with CAF levels as
a dichotomous variable, and low levels of FGF-2 (p <
0.0001), HGF (p < 0.05), IL-8 (p < 0.05), TNF-α (p < 0.05),
and VEGF (p < 0.005) were associated with better PFS.
Instead, only low levels of FGF-2 (p < 0.001) and VEGF
(p < 0.004) were associated with prolonged OS. Similar
results were obtained when CAF levels were related to
PFS and OS according to the combination therapy ad-
ministered. A better PFS was in fact related to low levels
of FGF-2 (p < 0.0001), HGF (p < 0.0001), TNF-α (p <
0.005), and VEGF (p < 0.005) in the VMP arm and
FGF-2 (p < 0.005) and VEGF (p < 0.05) in the VMPT-VT
arm. When OS was taken into consideration, only
FGF-2 (p < 0.001 in the VMP arm, p < 0.005 in the
VMPT-VT arm), and VEGF (p < 0.05 for both arms)
were demonstrated (Additional file 1: Table S3).
Hierarchical clustering analysis (Fig. 3) showed three
distinct risk groups of patients, based on the concentra-
tions of two CAF levels (FGF-2 and VEGF). Patients
with elevation of both CAF levels had a worse prognosis
with significantly shorter PFS and OS (high risk) com-
pared with those with high level of only one (p < 0.0001,
intermediate risk) and those of low blood levels of both
CAFs (p < 0.0001, low risk) (Fig. 3). No significant differ-
ences were detected depending on the type of therapy
received. Trying to construct a survival model, a
three-stage system using FGF-2 and VEGF blood levels
provided the highest statistically significant results
(Table 2). Median survivals of the risk groups were as
follows: low risk: PFS 44 months, OS 70 months; inter-
mediate risk: PFS 23.5 months, OS 62 months; and high
risk: PFS 14.5 months, OS 34 months (p < 0.0001 for dif-
ferences). Patient numbers were well distributed across
the three groups (low risk, 40%; intermediate risk, 29%;
and high risk, 31%).
By multivariate analysis (Table 3), the other variables
significantly associated with better outcome were age <
65 years in the intermediate- and high-risk groups (HR
0.61, CI 0.44–0.85, p = 0.0047 and HR 0.60, CI 0.38–
0.89, p = 0.0391, respectively) for OS; age < 65 years and
best response to induction therapy (≥VGPR) only in the
high-risk group (HR 0.68, CI 0.48–0.96, p = 0.0342) for
PFS. Durie and Salmon (D&S) stage 1 or 2 impacted
only on PFS for the high-risk group (HR 0.64, CI 0.49–
0.89, p = 0.0169). No significant differences were demon-
strated regarding both PFS and OS for sex, isotype of
the M-component, renal failure, and type of induction
therapy. The administration of maintenance therapy sig-
nificantly impacted on PFS in all the risk groups (low:
HR 0.70, CI 0.44–0.89, p = 0.0210; intermediate: HR
0.54, CI 0.38–0.80, p = 0.0008; high: HR 0.71, CI 0.56–
0.92, p = 0.0249) and OS (low: HR 0.70, CI 0.48–0.88, p
= 0.0210; intermediate: HR 0.74, CI 0.57–1.01, p =
0.0330; high: HR 0.52, CI 0.36–0.75, p = 0.0003).
As regards the cytogenetic risk, because many data
relative to the cytogenetic characteristics of the patients
were missing in the database of the trial, the statistical
power of the relative analysis was low. For this reason, it
is not possible to reach a correct conclusion on the value
of CAFs stratification risk in correlation to this risk
parameter.
Discussion
The emergence of new treatment options for MM has
extended the patients’ survival [5] and the need to pro-
spectively identify those patients who are likely to bene-
fit from a specific treatment and understand the
mechanisms underlying therapeutic resistance. Several
adverse prognostic factors have been identified in MM
at diagnosis and before initiation of treatment [38, 39],
including an advanced stage in the international staging
system (ISS) based on plasma albumin [40]. The dual ac-
tivity of the new and newest drugs active both on MM
plasma cells and bone marrow stromal cells, and in par-
ticular on angiogenesis [41–43], obviously indicates that
any new prognostic markers cannot ignore the angio-
genesis aspect. Previous studies have indeed suggested
that the plasma levels of CAFs might be used to identify
prognostic and predictive markers in solid tumors [44–
49] and are indicative of the response to antineoplastic
therapy [29–32].
Seven CAFs of the nine evaluated (ANG-2, FGF-2,
HGF, IL-8, PDGF-BB, TNF-α, and VEGF) initially
emerged as being related to disease activity, but further
testing showed that only FGF-2 and VEGF were signifi-
cantly associated with PFS and OS and were therefore
evaluated for prognostic stratification of patients. We
also assessed whether determination of the studied CAFs
could add prognostic information to D&S [50] and
International Staging Systems (ISS) [40] or whether
these systems were, in fact, predictive of benefit. D&S
and ISS staging were associated with prognosis based on
PFS in both groups; however, they were not strong prog-
nostic parameters as FGF-2 and/or VEGF. Thus, the
plasma levels of the two angiogenic cytokines provided
prognostic and, more importantly, predictive value be-
yond that of standard clinical staging.
Our analyses of survival were based on assignment at
initial randomization. High FGF-2 and VEGF plasma
levels were negative prognostic markers and were associ-
ated with lower relative OS in both harms. The associa-
tions reported here with FGF-2 and VEGF were akin to
previous studies [29–32], in which patients with the
highest reduction of circulating CAF concentrations ob-
tained the greatest benefit from anticancer therapy.
However, other studies assessing the use of VEGF as a
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predictive marker of benefit from VEGF-targeted therap-
ies in renal-cell carcinoma have yielded inconsistent re-
sults [51].
Previous studies have shown that groups of related an-
giogenic or inflammatory factors are often correlated
[44, 46, 52]. Hierarchical clustering of six circulating
CAFs showed a strong correlation among many of them,
including osteopontin and VEGF [46, 52]. Patients de-
fined by high concentrations of these CAF and inflam-
matory or immunomodulatory factors had a significantly
Fig. 3 Progression-free and overall survival analysis in MM patients based on the peripheral blood plasma concentrations of FGF-2 and VEGF. The
hierarchical clustering analysis of MM patients shows three distinct risk groups of patients based on the concentrations of FGF-2 and VEGF. High
risk: patients who present both high FGF-2 and VEGF plasma levels showing a worse prognosis with significantly shorter PFS and OS; intermediate
risk: patients who present high plasma levels in only one of the two cytokines; low risk: patients who show low blood levels in both angiogenic
cytokines. Again, no evident differences between the two therapy regimens were detected
Table 2 Patient stratification based on CAF circulating levels
Risk group Risk factors Criteria Median PFS (months) Median OS
(months)
Low 0 FGF-2 ≤ 950 pg/dL and
VEGF ≤ 19,000 pg/dL
38 67
Intermediate 1 FGF-2 > 950 pg/dL or
VEGF > 19,000 pg/dL
24 55
High 2 FGF-2 > 950 pg/dL and
VEGF > 19,000 pg/dL
15 37
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worse prognosis, but derived a greater relative OS bene-
fit from therapy. The circulating CAFs identified in these
studies might themselves have important biological roles
or might be markers for alternative pathways or mecha-
nisms affecting treatment responses (e.g.,
hypoxia-induced factor-1α or NF-κB pathways). This as-
sociation between factors suggests that common mecha-
nisms might regulate their production. Studying a
cohort of patients with metastatic renal-cell carcinoma,
a classification of the disease based on the higher ex-
pression of angiogenic versus inflammatory circulating
CAFs defined by a six-cytokine signature was established
[46]. In that study, the angiogenic group derived greater
benefit from sorafenib alone, whereas the other group
benefited from the combination of sorafenib and IFN-α.
In the present study, a similar correlation of treatment
benefit with circulating CAF signature was observed in
MM patients.
All the evidences provided by the studies on the role
of microenvironment [3, 17], and particularly of the an-
giogenic process [23, 37] in myeloma progression as well
as in cancer cell protection mediated by microenviron-
ment components [37], indicated that the response to
therapy is also related to the activity of anticancer drugs
on tumor microenvironment [42, 43]. Therefore, the in-
hibition of cytokine production which mediates the
interaction between cancer cells and their microenviron-
ment represents one of the major goals of the modern
therapeutic approaches. On these bases, the evaluation
of CAF levels is indicative of the response to therapy
and may represent a good indicator of refractoriness in
cancer patients.
Conclusion
Overall, our findings support the use of circulating CAF
profiling to define biologically distinct subgroups of MM
patients whose tumors have a greater angiogenic drive.
As such, these patients might have a more aggressive
disease course but are likely to derive relative benefit
from inhibition of angiogenic pathways. Circulating CAF
profiling might be particularly well suited for angiogen-
esis inhibitors and other drugs targeting the tumor
microenvironment, in which both circulating
host-derived and tumor-derived factors could affect re-
sponse. Such an approach may have important advan-
tages, including straightforward and relatively
non-invasive sample collection, availability of robust
analytical platforms, and the ability to monitor changes
during treatment or disease progression, which can help
identify markers of resistance.
The limitation of this study is that the results have
been obtained in older patients not-eligible for ASCT,
whereas the major strength of the study is the homoge-
neous stratification and longer follow-up of patients.
Further studies on a greater cohort of subjects, including
young patients eligible for ASCT before and after treat-
ment, will be needed to evaluate the variation of CAFs
after therapy, to study their power as an indicator of
Table 3 Multivariate analysis of risk stratification of patients based on the CAFs FGF-2 and VEGF
Variable PFS OS
Risk group Risk group
Low Intermediate High Low Intermediate High
HR
(95 CI)
p HR
(95 CI)
p HR
(95 CI)
p HR
(95 CI)
p HR
(95 CI)
p HR
(95 CI)
p
Sex 0.82
(0.59–1.18)
0.3698 0.74
(0.59–1.11)
0.9645 0.86
(0.62–1.08)
0.3438 0.80
(0.57–1.05)
0.3698 0.96
(0.68–1.33)
0.6905 0.86
(0.59–1.16)
0.5713
Age (< 65 years) 0.96
(0.69–1.35)
0.7647 0.87
(0.55–1.20)
0.2027 0.73
(0.59–0.98)
0.0455 0.97
(0.71–1.32)
0.7647 0.61
(0.44–0.85)
0.0047 0.60
(0.38–0.89)
0.0391
Isotype 0.91
(0.56–1.32)
0.2957 0.91
(0.64–1.31)
0.6951 0.96
(0.68–1.33)
0.6419 0.82
(0.51–1.21)
0.2957 0.83
(0.57–1.15)
0.3627 0.98
(0.81–1.22)
0.8179
D&S stage 0.84
(0.60–1.16)
0.3218 0.82
(0.57–1.22)
0.3505 0.64
(0.49–0.89)
0.0169 0.83
(0.59–1.11)
0.3218 0.98
(0.67–1.44)
0.7874 0.74
(0.59–1.12)
0.0593
ISS stage 0.94
(0.66–1.29)
0.8163 0.91
(0.55–1.24)
0.2107 0.84
(0.58–1.28)
0.0619 0.79
(0.61–1.07)
0.1087 0.97
(0.66–1.34)
0.5221 0.87
(0.62–1.27)
0.0665
Cytogenetic risk 0.93
(0.64–1.28)
0.6358 0.87
(0.56–1.22)
0.3451 0.91
(0.55–1.33)
0.6670 0.86
(0.71–1.32)
0.2399 0.89
(0.69–1.41)
0.6133 0.92
(0.71–1.37)
0.6112
Renal failure 0.94
(0.61–1.25)
0.5866 0.92
(0.59–1.44)
0.6957 0.87
(0.60–1.21)
0.2410 0.92
(0.66–1.41)
0.5866 0.94
(0.71–1.35)
0.6108 0.97
(0.74–1.25)
0.8902
Induction therapy 0.84
(0.61–1.28)
0.3520 0.93
(0.66–1.34)
0.6838 0.88
(0.58–1.18)
0.3356 0.84
(0.57–1.19)
0.3520 0.93
(0.70–1.32)
0.6075 0.89
(0.66–1.28)
0.6015
Best response to
induction therapy (≥ VGPR)
0.76
(0.59–1.18)
0.0984 0.68
(0.48–0.96)
0.0342 0.71
(0.55–1.08)
0.0533 0.74
(0.59–1.09)
0.0984 0.95
(0.69–1.31)
0.5031 0.88
(0.61–1.29)
0.0583
Maintenance 0.70
(0.44–0.89)
0.0210 0.54
(0.38–0.80)
0.0008 0.71
(0.56–0.92)
0.0249 0.70
(0.48–0.88)
0.0210 0.74
(0.57–1.01)
0.0330 0.52
(0.36–0.75)
0.0003
p values less than 0.05 was considered significant
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minimal residual disease and, then, of risk of relapse,
and to evaluate the value of the risk stratification based
on CAFs in the new drugs era, with the aim of defini-
tively establish the value of this approach in the applica-
tion of precision, personalized therapy for patients with
MM.
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